当前位置: 首页 > 期刊 > 《糖尿病新世界》 > 2017年第22期
编号:13251962
胰岛素治疗血糖控制不佳的2型糖尿病患者联合达格列净的疗效及安全性(3)
http://www.100md.com 2017年11月15日 《糖尿病新世界》 2017年第22期
     [參考文献]

    [1] Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States,2014[EB/OL].Available at:http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf.

    [2] Yu Xu, Limin Wang,J He,et al. Prevalence and Control of Diabetes in Chinese Adults [J].JAMA.2013,310(9):948-959.

    [3] Stark Casagrande S, Fradkin JE,et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010[J]. Diabetes Care, 2013,36(8):2271-2279.

    [4] 曹娜.高血压与胰岛素抵抗、高胰岛素血症的关系[J].河北医药,2011,33(3):390-391.

    [5] Misra M.SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus[J] .Journal of Pharmacology,2013,65(3):317-327.

    [6] Neumiller JJ,White JR,Campbell RK. Sodium-glucose cotransport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus[J].Drugs,2010, 70(4):377-385.

    [7] American Diabetes Association.Standards of medical care in diabetes 2015[J]. Diabetes Care, 2015,38:S(1)S1-S90.

    (收稿日期:2017-08-18), 百拇医药(陈晓蕾 贾农 杨林 蔡丽萍 夏连丽 杨锐林 宋琳)
上一页1 2 3